The Board discussed and passed the following resolutions: 1. To consider, approve and take on record the un-audited financial results of the company for the quarter ended 30th June, 2025. 2. ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts more than Nifty Microcap 250 and 1.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Phaarmasia Ltd's Board of Directors met on August 11, 2025, and approved the unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26), along with noting the Limited Review Report for the same period. The Board also approved convening the 44th Annual General Meeting, including the draft Directors' Report, Notice of AGM, and appointment of a scrutinizer for e-voting. Additionally, Mr. Naga Bhaskarrao Yallapragada, a Whole-Time Director, was reappointed (retiring by rotation), and his remuneration was increased. The Secretarial Audit Report for FY25 and the MD & CFO certificate for Q1 FY26 were also noted.
This is a routine quarterly compliance filing confirming Q1 results approval and AGM preparation. Shareholders should watch for the actual Q1 numbers in the published results and note the increase in remuneration of the Whole-Time Director, which requires shareholder approval at the upcoming AGM.